Fig. 1
From: Precision therapeutic targets for HPV-positive cancers: an overview and new insights
Direct targeting of HPV. Illustration of RNAi, gene editing, protein-targeting with small molecules/antibodies and immunotherapy. The RNAi leads to homology-dependent degradation of the target mRNA. The CRISPR system recognizes and cleaves the HPV genome. Small molecule drugs/antibodies directly bind to oncoproteins and inhibit their function. Immunotherapy promotes the immune response of the host. Created in BioRender.com